GlobeNewswire·Nov 12, 2026, 7:30 AM ET

Sagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

SGMT

Sagimet initiated the registrational U.S. AURORA Phase 3 clinical trial for denifanstat in moderate to severe acne, with topline data expected in the second half of 2027.
The AURORA trial will enroll approximately 800 patients aged 12 years and older, including about 450 adolescents aged 12 to 17 years, to support a potential U.S. New Drug Application.
Positive 52-week results from the denifanstat Phase 3 open-label extension trial conducted by license partner Ascletis in China were presented at EADV 2026 & Fall Clinical Dermatology 2026, showing sustained efficacy across all endpoints.
Sagimet completed an underwritten offering of Series A common stock & pre-funded warrants in October 2026, generating $115 million in gross proceeds.
The company holds a pro forma cash balance of approximately $356 million as of September 30, 2026, which is expected to fund operations through mid-2029, covering the AURORA data readout & potential NDA submission.
Phase 1 clinical trials for the FASN inhibitor TVB-3567 completed dosing & demonstrated good tolerability, with a Phase 2 trial in moderate to severe acne anticipated to start before the end of 2026.
Research & development expenses for the nine months ended September 30, 2026, were $34.9 million, while general & administrative expenses were $14.2 million.
The company reported a net loss of $43.8 million for the nine months ended September 30, 2026, compared to $41.5 million in the same period of 2025.
Denifanstat represents the first oral acne treatment with a novel mechanism of action potentially approved by the FDA in over 40 years if successful.
Sagimet continues development of a topical FASN inhibitor formulation for the potential treatment of acne.

Company: Sagimet Biosciences Inc.
Keywords: Nasdaq:SGMT, Sagimet Biosciences Inc.